Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07347977 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk

Study acronym: LidCRM
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients. Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge
Trial Details
NCT Number NCT07347977
Lead Sponsor First Affiliated Hospital of Ningbo University
Collaborators: Second Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, Recurrence, Survival Analysis
Related terms Carcinoma, Non-Small-Cell Lung, Recurrence
Enrollment 1,400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov